Risk factors for cognitive impairment in patients with first-time ischemic stroke

Guotao Yang1, Conghui Li1, Wenhui Wang1

  • 1Department of The Third Neurology, Cangzhou Central Hospital Cangzhou 061000, Hebei, China.

Insights

Cognitive impairment (CI) affects over half of first-time ischemic stroke patients. Key risk factors include advanced age, diabetes, high CRP and Hcy levels, and stroke severity.

Area of Science:

  • Neurology
  • Stroke Medicine
  • Cognitive Science

Background:

  • Cognitive impairment (CI) is a common complication following ischemic stroke.
  • Identifying risk factors for CI is crucial for timely intervention and improved patient outcomes.

Purpose of the Study:

  • To investigate the independent risk factors associated with cognitive impairment in patients experiencing their first ischemic stroke.

Main Methods:

  • Retrospective analysis of clinical data from 180 first-time ischemic stroke patients.
  • Patients were categorized into cognitive impairment (MMSE score ≤24) and normal groups.
  • Multivariate logistic regression analysis was employed to identify risk factors.

Main Results:

  • Cognitive impairment (CI) was observed in 53% of patients.
  • Large-artery atherosclerosis subtype and frontal lobe infarction showed higher CI incidence.
  • Independent risk factors identified: age ≥60, diabetes, elevated CRP (>6.53 mg/L), elevated Hcy (>13.84 μmol/L), high NIHSS score (>4.37), and low VD (<45.16 nmol/L).

Conclusions:

  • First-time ischemic stroke patients exhibit a high incidence of cognitive impairment.
  • Age, diabetes, specific inflammatory markers (CRP, Hcy), stroke severity (NIHSS), and vascular factors (VD) are significant predictors of CI.
Abstract

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
2.2K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
600
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
276
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
241
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
291
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
173